Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bare Escentuals plans stock sale

This article was originally published in The Rose Sheet

Executive Summary

Firm is offering 8 mil. shares at an initial price of $36.50 apiece to raise $2.9 mil. in funds to be used for "general corporate purposes and working capital," Bare Escentuals announces June 14. The company itself will sell 100,000 shares; the remaining 7.9 mil. will be sold by shareholders, including members of Bare Escentuals' management. The sale will reduce Berkshire Partners LLC's stake in the firm from 29.9% to 25.5% and JH Partners LLC's interest from 14% to 11.9%. Goldman Sachs is the lead underwriter for the offering, and some stockholders have offered the underwriters an option to purchase up to 1.2 mil. additional shares...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014794

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel